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Abstract
Retrospective testing of predictive models does not consider the real-world context in which models are de-
ployed. Prospective validation, on the other hand, enables meaningful comparisons between data generation
processes by incorporating trained models and considering the subjective decisions that affect reproducibility.
Prospective experiments are essential for consistent progress in modeling.
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“You keep using that word”
As the Man in Black clings to the Cliffs of Insan-
ity in Rob Reiner’s 1987 film The Princess Bride,
Vizzini exclaims, “Inconceivable!” Inigo Montoya
responds: “You keep using that word. I do not
think it means what you think it means.” If Inigo
had studied chemistry rather than swordplay he
might have said the same thing about ‘validation’
of machine learning models and marveled at the
disconnects that exist between model building and
application.
Modeling in drug discovery is fundamentally driven
by time: the molecules we make (or buy) today of-
ten look different than the ones we made yester-
day or that we’ll make tomorrow. This introduces
covariate shift [1] into our datasets and requires
continuous model updates to keep the applicabil-
ity domain aligned with synthetic efforts. Tempo-
ral considerations have also become prominent in
model building, particularly with the introduction
of time-split cross-validation [2].
A misunderstanding persists in the literature that
temporal data splits are equivalent to prospective
validation. In time-split cross-validation, models
are trained on data generated before a certain date
and tested on a held-out set of data generated af-
ter that date. However, this procedure makes an
assumption about the data generation process that
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is violated by real-world application of the trained
model: it does not consider the role of the model in
compound selection.
In most programs a complicated process integrat-
ing signals from medicinal chemists and predictive
models is used to select the next batch of com-
pounds for synthesis (more on that below). Intro-
ducing a new predictive model into this process will
change the set of compounds that are synthesized
such that the held-out set used to assess model per-
formance is less representative of actual future data.
Said another way, time-split cross-validation—like
all other retrospective methods—can only tell you
about how the model will perform if it is never used
in the decision-making process.
A Prospective Perspective
True prospective validation uses the trained model
to select compounds for testing. The model must
have “skin in the game” to measure its effect on
the data generation process [3]. Depending on the
process used to select compounds, prospectively in-
corporating the trained model may have different
effects. For instance, the model may prioritize com-
pounds that would not have been made in the orig-
inal process or downvote molecules that would oth-
erwise have been tested. The model could affect
confidence estimates—perhaps the compound rank-
ings are unchanged but predictions are more or less
accurate than before.
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It is critical to emphasize that prospective studies
validate processes and not models. While a pre-
dictive model may be part of a data generation
process, it is not the only part: there are often
choices to make regarding training data selection
and preparation, input featurization, hyperparam-
eter domains and optimization strategies, filtering
or clustering of model output, integration of signals
from chemists or other models, synthetic feasibility
estimates, material costs and availability, and so
on. All of these parameters affect the output of
the process (i.e., the compounds that are selected
for synthesis) and they may dilute or mask the per-
ceived value of model-specific choices if they are not
carefully controlled.
Many real-world processes include highly subjective
components that make meaningful comparisons dif-
ficult. Consider a process that includes prioritiza-
tion of model predictions by one or more medicinal
chemists. If multiple chemists are involved, the ef-
fect of the change may not be consistent over re-
peated runs of the process; different chemists are
likely to select different compounds [4], and the
comparison could be repeated multiple times to get
a distribution of expected outcomes. If one chemist
does all of the selections, prospective validation
should include selections from both the original and
updated model predictions since individual prefer-
ences can change over time—the key principle is
that process changes should be evaluated by com-
parisons starting from the same initial state. Note
that the validation results will be most representa-
tive of future performance if the same chemist(s)
are also involved in downstream applications of the
model.
From Cogs to Machines
The impact of modeling changes may be attenuated
or amplified by subjective decisions in the overall
data generation process. Just as a model cannot
perform better than the experimental error of the
data, subjective process decisions limit the confi-
dence we can have when assigning credit to mod-
eling choices. In the worst cases, subjectivity can
reduce otherwise meaningful comparisons to anec-
dotes.
One way to reduce subjectivity in prospective val-
idation is to design automated workflows that ap-
proximate real-world processes. For instance, prior-
itization of model predictions by a chemist could be
replaced by predetermined filtering criteria or aux-
iliary models that remove undesirable compounds.
McCloskey et al. recently took this approach
by employing “automated or automatable filters”
when selecting compounds to test models trained
on DNA-encoded library selection data [5]. Auto-
mated decisions are also important components of
closed-loop optimization systems [6].
The downside of automation is that it ignores
“chemical intuition” and other decision-making cri-
teria that are difficult to codify [7]. Fortunately,
even if an automated workflow is not actually used
in downstream applications it can serve as a robust
platform for prospective validation to the degree
that automated decisions are reasonable proxies for
their more subjective counterparts. This immedi-
ately suggests another experiment: prospective val-
idation can be used to compare a real-world process
to its automated analog! And of course, prospective
validation can be used to evaluate changes to any
process regardless of whether it involves modeling.
Moving Forward
We acknowledge that the financial and opportunity
costs required for prospective experiments are not
trivial and require larger-than-typical investments
from organizations and teams. It would of course
be impractical to demand that every model vali-
dation be prospective. Retrospective benchmarks
like MoleculeNet [8] are useful for broadly compar-
ing new model architectures across many possible
application domains. Competitions like the Merck
Molecular Activity Challenge [9] create “common
task frameworks” [10] that reduce overfitting to test
data. Task-specific retrospective validation (includ-
ing time-split cross-validation) is helpful for iden-
tifying hyperparameter sensitivities and as a san-
ity check before investing additional resources into
prospective studies.
Caveats aside, prospective validation is an essen-
tial tool for modern drug discovery. It provides the
most realistic view of future performance by match-
ing the actual setting for downstream applications
and allows for direct comparisons with existing pro-
cesses. As models are given more resources and a
correspondingly larger role in discovery, systematic
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experiments that quantify and control for subjec-
tive variability enable accurate credit assignment
to specific modeling decisions and other perturba-
tions of data generation processes. It is this accu-
rate credit assignment—enabled by true prospec-
tive validation—that will set the stage for a fu-
ture where chemists and modelers work together to
create reproducible discovery processes that provide
clear signals for optimization.
Inigo Montoya’s all-consuming quest to avenge the
murder of his father by the six-fingered man eventu-
ally came to an end, but our quest is just beginning.
As a field, we must adopt a prospective perspec-
tive. This includes (i) holding up prospective vali-
dation as the most reliable way to estimate model
performance; (ii) acknowledging the incompleteness
of retrospective validation in our own work and
peer reviews; and (iii) adjusting our data genera-
tion processes and validation workflows to give ro-
bust, reproducible results. Only in this way can we
avenge ourselves of anecdotal reports and apples-to-
oranges comparisons that hold us back from consis-
tent progress.
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